Compound Detail
CHEMBL3544964
RAVOXERTINIB 🧪 Phase II
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase II
Basic Information
| ChEMBL ID | CHEMBL3544964 |
| Name | RAVOXERTINIB |
| Phase | Phase II |
| Structure Type | MOL |
| InChI Key | RZUOCXOYPYGSKL-GOSISDBHSA-N |
18
Targets
33
Activities
2
Assay Types
21
PK Parameters
20
Publications
4
Known Names
1
Indications
2
Mechanisms
Molecular Properties
440.9
MW (Da)
3.16
ALogP
8
HBA
2
HBD
97.9
PSA (Ų)
0.48
QED
0
Ro5 Violations
6
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| MAP kinase ERK1 inhibitor | INHIBITOR | Mitogen-activated protein kinase 3 | ✓ | ✓ |
| MAP kinase ERK2 inhibitor | INHIBITOR | Mitogen-activated protein kinase 1 | ✓ | ✓ |
Indications
Neoplasms
Activity Summary
Kd 21 meas. best 8.8
IC50 12 meas. best 9.52
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Mitogen-activated protein kinase 1 CHEMBL4040 | IC50 | 9.52 | 8.1517 | 0.3 | 6 |
| Mitogen-activated protein kinase 3 CHEMBL3385 | IC50 | 8.92 | 8.565 | 1.2 | 2 |
| Mitogen-activated protein kinase 1 CHEMBL4040 | Kd | 8.8 | 8.42 | 1.6 | 3 |
| Unchecked CHEMBL612545 | IC50 | 7.92 | 7.92 | 12.0 | 1 |
| Mitogen-activated protein kinase 3 CHEMBL3385 | Kd | 7.72 | 7.72 | 19.0 | 1 |
| Mitogen-activated protein kinase; ERK1/ERK2 CHEMBL1907606 | IC50 | 7.51 | 7.29 | 31.0 | 2 |
| Calcium/calmodulin-dependent protein kinase type 1G CHEMBL5258 | Kd | 6.93 | 6.93 | 117.0 | 1 |
| Serine/threonine-protein kinase TAO1 CHEMBL5261 | Kd | 6.64 | 6.64 | 230.0 | 1 |
| Hepatocyte growth factor receptor CHEMBL3717 | Kd | 6.42 | 6.42 | 378.0 | 1 |
| AP2-associated protein kinase 1 CHEMBL3830 | Kd | 6.4 | 6.4 | 401.0 | 1 |
| Uncharacterized protein FLJ45252 CHEMBL4105933 | Kd | 6.33 | 6.33 | 466.0 | 1 |
| Glycogen synthase kinase-3 beta CHEMBL262 | Kd | 6.22 | 6.22 | 599.0 | 1 |
| Glycogen synthase kinase-3 alpha CHEMBL2850 | Kd | 5.66 | 5.66 | 2186.0 | 1 |
| BMP-2-inducible protein kinase CHEMBL4522 | Kd | 5.53 | 5.53 | 2985.0 | 1 |
| Platelet-derived growth factor receptor beta CHEMBL1913 | Kd | 5.4 | 5.4 | 3988.0 | 1 |
| Cyclin-dependent kinase 13 CHEMBL1795192 | Kd | 5.24 | 5.24 | 5744.0 | 1 |
| Activin receptor type-1 CHEMBL5903 | Kd | 5.23 | 5.23 | 5859.0 | 1 |
| Unchecked CHEMBL612545 | Kd | 5.09 | 5.09 | 8200.0 | 1 |
| Beta-adrenergic receptor kinase 1 CHEMBL4079 | Kd | 4.75 | 4.75 | 17728.0 | 1 |
| Mitogen-activated protein kinase 6 CHEMBL5121 | IC50 | 4.66 | 4.66 | 21800.0 | 1 |
| Mitogen-activated protein kinase 6 CHEMBL5121 | Kd | 4.6 | 4.56 | 25000.0 | 3 |
| Cyclin-G-associated kinase CHEMBL4355 | Kd | 4.57 | 4.57 | 27114.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 15.0 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 19.0 | mL.min-1.kg-1 | Mus musculus |
| CL | 6.4 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 31.0 | mL.min-1.kg-1 | Macaca fascicularis |
| F | 35.0 | % | Rattus norvegicus |
| F | 39.0 | % | Mus musculus |
| F | 112.0 | % | Canis lupus familiaris |
| F | 15.0 | % | Macaca fascicularis |
| Fu | 0.044 | - | Rattus norvegicus |
| Fu | 0.058 | - | Mus musculus |
| Fu | 0.098 | - | Canis lupus familiaris |
| Fu | 0.056 | - | Macaca fascicularis |
| Fu | 0.08 | - | Homo sapiens |
| Ka | 6.2 | 10'-6/M/s | Homo sapiens |
| Ka | 9.8 | 10'-6/M/s | Homo sapiens |
| T1/2 | 0.02 | hr | Homo sapiens |
| T1/2 | 0.01333 | hr | Homo sapiens |
| T1/2 | 2.0 | hr | Rattus norvegicus |
| T1/2 | 1.3 | hr | Mus musculus |
| T1/2 | 6.8 | hr | Canis lupus familiaris |
| T1/2 | 2.4 | hr | Macaca fascicularis |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine